Contribute Try STAT+ Today

A shift toward making multiple medications under one roof is sparking concern about what happens when a facility suddenly shuts down because of a manufacturing or safety issue: Closing a single factory could lead to shortages of hundreds of drugs, say regulators and industry analysts.

Their anxiety is complicated by the tight secrecy surrounding where pharmaceuticals are made, so even experts aren’t certain where or how a supply problem has occurred.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Reminds me of the good old days, when some of the manufacturers would have all their anti-infectives on an island south of Florida, that had to deal with hurricaines ever year and the plant would get damaged and then we had to deal with how to treat patients because of shortages (not FDA/483, etc. related). I just came out of industry and would discuss API (Active Pharmaceutical Ingredient) with our commercial folks who negotiated the API and how a couple companies controlled most of the anti-infectives needed to make drugs, etc. through out the world. When I was in hospital practice when it came to generic drugs, I always wanted to know where the API came from and I would purchase that product, because it was more important to treat patients, than save a few bucks. In the long run, it could actually cost more by having to switch to a different class of drug or another generic.

  • The “red devil” is Adriamycin which is also doxorubicin but not liposomal like Doxil.

Comments are closed.